Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carisbamate SCHEMBL2425732 | 1.00 | AOC3 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL729003 | 1.00 | AOC3 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL8741032 | 0.95 | ADRB2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Carisbamate SCHEMBL8741086 | 0.95 | ADRB2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL13001768 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL10216882 | 0.83 | CYP1A2 (0.49) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| SCHEMBL14200056 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL14200054 | 0.83 | CASP1 (0.49) | AOC3CYP1A2CYP2D6CASP1ADRB2 | |
| SCHEMBL13879248 | 0.82 | CASP1 (0.48) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM | |
| Hydrochloric Acid SCHEMBL3446916 | 0.82 | CYP1A2 (0.47) | AOC3CYP1A2CYP2D6SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | claimed |
| EP-2276481-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | Janssen Pharmaceutica, N.V. (BE) | 2011-01-26 | — | — | EP | claimed |
| US-7632963-B2 | Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-15 | — | — | US | claimed |
| WO-2009120189-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | WO | claimed |
| US-20090247616-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | claimed |
| EP-2076258-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | Janssen Pharmaceutica, N.V. (BE) | 2009-07-08 | — | — | EP | claimed |
| EP-2076135-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | Janssen Pharmaceutica, N.V. (BE) | 2009-07-08 | — | — | EP | claimed |
| US-20080194860-A1 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | claimed |
| WO-2008063284-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-29 | — | — | WO | claimed |
| WO-2008045391-A2 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-17 | — | — | WO | claimed |
| US-20080085930-A1 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2008-04-10 | — | — | US | claimed |
| EP-2248799-B1 | PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL)-2-HYDROXY-ETHYL CARBAMATES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-05-20 | — | — | EP | disclosed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2076258-A4 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2276481-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | Janssen Pharmaceutica, N.V. (BE) | 2011-01-26 | — | — | EP | disclosed |
| US-20080085930-A1 | NOVEL CRYSTAL OF (S)-(+)-2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2008-04-10 | — | — | US | disclosed |
| EP-1406606-B1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEUROPATHIC PAIN AND CLUSTER AND MIGRAINE HEADACHE-ASSOCIATED PAIN | ORTHO MCNEIL PHARM INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1461309-A1 | PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL) - 2 - HYDROXY-ETHYL CARBAMATES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003053916-A1 | PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL) - 2 - HYDROXY-ETHYL CARBAMATES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-5698588-A | OPTICALLY PURE ENANTIOMERIC FORM; TREATING CENTRAL NERVOUS SYSTEM DISORDERS | YUKONG LIMITED (KR) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247616-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | GABBR1, GABBR2, XDH | AOC3 997/4885CYP1A2 133/4885CYP2D6 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.